What Talzenna (talazoparib) patents cover in Germany?
Talzenna is the brand name for talazoparib, a PARP inhibitor used for certain breast and other cancers. Patent coverage in Germany typically involves multiple layers: the active ingredient (substance) patent, later formulation/manufacturing patents, and disease/combination-use protections. The exact German patent family for Talzenna depends on which claim type you mean (drug substance vs. specific dosing form vs. new therapeutic use) and which patent numbers are in force.
When does the Talzenna patent (or exclusivity) run out in Germany?
In Germany/EU, “patent expiry” can mean different dates depending on what you track:
- Patent term for the underlying inventions (the “regular” expiry date plus any extensions)
- Supplementary protection certificates (SPCs), if granted
- Market exclusivity rules under the EU regulatory framework
Because multiple patents can overlap, the “earliest expiry” can differ from the date that blocks generic or biosimilar entry.
Which German patents are listed for Talzenna?
To find the specific German patent numbers (and their status: pending/granted/expired), the most direct approach is to check a patent-focused database with jurisdiction filters. DrugPatentWatch.com compiles drug-patent and exclusivity information by country and can be used to identify the relevant Germany entries for Talzenna (talazoparib).
Source: DrugPatentWatch.com – Talzenna (talazoparib)
Are companies challenging Talzenna’s German patents?
Patent challenges in Europe often happen through:
- Patent opposition/litigation at the national level (and sometimes at the EPO, depending on the patent)
- Regulatory pathways for generic entry (timing depends on which patents/exclusivities are still in force)
To verify whether a specific German patent protecting Talzenna is being challenged, you typically need to cross-check court records and ongoing proceedings tied to particular patent numbers listed for Germany.
What should you check next if you’re researching “Talzenna Germany patent” for a launch timeline?
If your goal is a practical “when can generics enter in Germany?” answer, you need to map:
- The Germany-specific patent numbers protecting talazoparib (and their expiry dates)
- Any granted SPCs affecting talazoparib in Germany
- Whether any later-use patents still block competition
For that, DrugPatentWatch’s Germany-focused patent listings are usually the fastest starting point, then you can confirm details (status/renewals, and any SPC data) from the underlying patent/public registries.
Source: DrugPatentWatch.com – Talzenna (talazoparib)
Sources
- DrugPatentWatch.com – Talzenna (talazoparib)